Solutions>CGP>TARGT First DNA CGP Kit (RUO)

TARGT First DNA CGP Kit (RUO)
Comprehensive Genomic Profiling for ALL

TARGT First DNA CGP Kit (RUO) is streamlined tumor NGS assay developed to profile genomic alterations: SNVs/InDels, CNAs, and Gene Fusions/Splice Variants in 53 well curated genes in pan solid tumors. Solid tumor types of interest includes lung, breast, ovarian, colorectal, and prostate.

53 well curated genes were selected to cover the somatic variants associated with these solid tumor types in the guidelines of Food and Drug Administration (FDA), National Comprehensive Cancer Network (NCCN), the College of American Pathologists (CAP), and the European Society for Medical Oncology (ESMO).

0.7 Mb Panel size will requires less sequencing data to generated molecular insights making it time and cost effective.

Unique panel design can detect gene fusions/splicing (ALK, ROS1, RET and METEx14 skipping) from single NGS assay (using DNA-seq data).

Book my Test

TargtFirstCGPKit

 
  Available in 2 Variants
DNA 48 RXNS 96 RXNS
Features & Benefits
  • Somatic mutation analysis from FFPE, Fresh Tissue, Blood and cell line.
  • High throughput massively parallel next-generation sequencing of pan–solid cancer genome.
  • DNA sequencing from different sample sources for solid cancers.
  • The kit assesses FDA-approved and NCCN-recommended genomic biomarkers for pan-solid cancers.
  • The kit is rigorously validated in the Indian cancer patient cohort to give a finer resolution of the mutation from the tumour genome that drives the disease in this part of the world.

Compact Panel design

  • 0.7 Mb panel targeting complete coding region including hotspots in 53 genes based on Standard of Care guidelines/FDA approvals

Easy to Implement

  • Compatible with Low input requirements; wide sample sources for pan solid tumors and muktipole sequencing platforms

Coverage and Depth

  • Excellent coverage with >99% across all the genes
  • Aiming for 500X sequencing depth

Performance metrics

  • 100% specificity and > 98% sensitivity. 100% accuracy, precision, and reproducibility. Our LOD is 5% for SNV and 10% for InDels (<10 bp)

Cost and Time Effective

  • Small panel size and less sequencing data making the panel cost effective

Comprehensive and Simplified Reports

  • Comprehensive analysis and reporting of small variants, insertions, deletions, amplifications, gene fusion/skipping (ALK/ROS1/RET/MET Exon14) fusions in multiple genes simultaneously.

Resources

TARGT First DNA Library Preparation Protocol
TARGT First DNA Gene list
Explore 4baseCare Solutions
Book my Test
loader